Postpartum Depression (PPD) affects between 10-15% of new mothers. PPD causes mothers to suffer from a long-lasting depression that, if severe, can put both the mother and the child in danger. Though PPD is common, available antidepressants are not guaranteed to help. A new treatment, brexanolone, offers hope for some mothers but also has severe side effects.
Read More »Tag: brexanolone
NCHR Testimony on Brexanolone for Postpartum Depression
November 2, 2018. We urge the committee to require more persuasive evidence on the safety of this drug. It is our moral obligation to patients to make sure that all drugs with this risk potential are scrutinized and held to a higher standard in the approval process.
Read More »